Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Influx HealthtechNSE:INFLUX +1.20%22 ROC (Joel Greenblatt) % is 54.78% as of Mar. 2026, which is 55% below its 10-year median of 121.18. GuruFocus rates NSE:INFLUX with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 980 Drug Manufacturers companies, Influx Healthtech ranks better than 87.24% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Influx Healthtech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 54.78%.
The historical rank and industry rank for Influx Healthtech's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:INFLUX'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 60.21 Med: 121.18 Max: 197.55
Current: 60.21
During the past 5 years, Influx Healthtech's highest ROC (Joel Greenblatt) % was 197.55%. The lowest was 60.21%. And the median was 121.18%.
NSE:INFLUX's ROC (Joel Greenblatt) % is ranked better than 87.24% of 980
companies
in the Drug Manufacturers industry
Industry Median: 11.695
vs NSE:INFLUX: 60.21
Influx Healthtech's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Influx Healthtech ROC (Joel Greenblatt) % Related Terms
Influx Healthtech ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INFLUX vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 54.78% mean?
Influx Healthtech (NSE:INFLUX) has a ROC (Joel Greenblatt) % of 54.78% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Influx Healthtech and its competitors. This is 55% below median its historical median of 121.18. Over the past decade, Influx Healthtech's ROC (Joel Greenblatt) % has ranged from 60.21 to 197.55. According to the industry distribution chart, Influx Healthtech ranks #125 out of 980 companies in the Drug Manufacturers industry, placing it in the top 12.8%.
Is Influx Healthtech's ROC (Joel Greenblatt) % too high?
Influx Healthtech's current ROC (Joel Greenblatt) % of 54.78% is 55% below median its 10-year median of 121.18. Over the past 10 years, this metric has ranged from a low of 60.21 to a high of 197.55. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.70. Influx Healthtech's value of 54.78% is 368.4% above this industry median. Based on the distribution chart, Influx Healthtech ranks #125 out of 980 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Influx Healthtech has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #125 out of 980 companies for ROC (Joel Greenblatt) %. This places Influx Healthtech in the top 13% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.70. Influx Healthtech's value of 54.78% is 368.4% above this benchmark. Historically, Influx Healthtech's own ROC (Joel Greenblatt) % has ranged from 60.21 to 197.55 over the past decade. While the company's 10-year median is 121.18 vs. the industry median of 11.70, Influx Healthtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.70, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current ROC (Joel Greenblatt) % of 54.78% is 368.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current ROC (Joel Greenblatt) % is 54.78%, which is 55% below median its own 10-year median of 121.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current ROC (Joel Greenblatt) % of 54.78%. The current ROC (Joel Greenblatt) % is 54.78%, which is 55% below median its 10-year median of 121.18 and 368.4% above the Drug Manufacturers industry median of 11.70. Influx Healthtech's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current ROC (Joel Greenblatt) % is 54.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
22GF Score
Get the complete analysis for NSE:INFLUX
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 
